The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer

Kelly J. Cude, Jeffrey S. Montgomery, Douglas K. Price, Shannon C. Dixon, Randall L. Kincaid, Karl F. Kovacs, David J. Venzon, David J. Liewehr, Margaret E. Johnson, Eddie Reed, William D. Figg*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

The androgen receptor plays a major role in the development and function of normal and malignant prostate cells. Due to the relationship of the androgen receptor and prostatic growth, it has been proposed that polymorphisms within the androgen receptor may play a role in an individual's susceptibility to developing prostate cancer. An inverse relationship has been established between a highly polymorphic trinucleotide repeat located in the first exon of the androgen receptor and the trans-activaton function of the receptor. Serum samples were collected from 131 patients with histologically confirmed adenocarcinoma of the prostate, DNA was isolated, and the polymorphic CAG repeat was amplified by PCR and sequenced. The CAG repeat lengths were then compared with age at diagnosis, age at time of study, base-line log10 PSA, Gleason score, time from diagnosis to ini- tiation of hormonal therapy, time to progression after androgen ablation, and overall survival time. No correlation was found between CAG length and time to progression or overall survival time, but a significant correlation was found between Gleason score and CAG length suggesting that shorter CAG lengths may predict a higher histological grade of prostate cancer.

Original languageEnglish
Pages (from-to)16-23
Number of pages8
JournalUrologia Internationalis
Volume68
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Keywords

  • Androgen receptor
  • CAG trinucleotide repeat
  • Prostate cancer

Fingerprint

Dive into the research topics of 'The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer'. Together they form a unique fingerprint.

Cite this